

Neuro-Oncology Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Mutations- diffuse midline glioma

1L

NRG-BN011

MGMT methylated only, IDH WT

Randomized: RT+TMZ vs RT+TMZ+CCNU

Coord: Hanh Ngo
Accrual: 3/5

UCI 23-198

Randomized: NaNO2 vs Placebo

Methylated and unmethylated allowed; IDH
WT; IV medication

PRMC approved

UCI 22-83

H3K K27M mutant mid-line glioma

Randomized: ONC201 vs Placebo

Coord: Hanh Ngo
Accrual: 0/4

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

2L

UCI 22-58

Only Part C open

Randomized: Vaccine vs CCNU

1st recurrence only, measurable disease not required after Sx;
IDH WT; multifocal disease not ok.

Coord: Daniel Na
Accrual: 0/6

NRG BN010 (opened on 2/1/24)

Randomized: Monotherapy + FSRT vs Combination therapy +
FSRT

1st recurrence only; IDH WT; multifocal disease ok; patients
need to be candidates for re-radiation; requires measurable
disease.

Coord: Hanh Ngo
Accrual: 0/6

23-67 (opened on 2/1/24)

Open Label monotherapy

Phase 1 only; needs DLL3 expression (found in 40%
population only); broader patient population-HGG and LGG
and IDH mut also included; phase 1 so will be intermittently
closed for analysis; multifocal disease allowed; any number of
recurrence ok.

Coord: Hanh Ngo
Accrual: 0/5



LGG

1L

Alliance N0577
1p/19q co-deletion

Randomized: TMZ vs PCV

Coord: Hanh Ngo
Accrual: 2/5

HGG

2L

23-67 (opened on 2/1/24)
Open Label monotherapy

Phase 1 only; needs DLL3 expression (found in 40% population only); broader patient population-HGG and LGG and IDH mut also included; phase 1 so will be intermittently closed for analysis; multifocal disease allowed any number of recurrence ok.

Tumor histologies: astrocytoma IDH mutant WHO Grade 2-4 and oligodendroglioma IDH mutant and 1p19q co-deleted WHO grade 2-3

Coord: Hanh Ngo
Accrual: 0/5

Meningioma

1L

[NRG-BN003](#)

Randomized: Observation vs RT

Coord: Hanh Ngo

Accrual: 2/5

Craniopharyngioma

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

2L

[UCI 20-152](#)

Cohort 2 open (non-heavily pre-treated)

Coord: Daniel Na

Accrual: 7/10

[A071401](#)

Only AKT1/PIK3CA/PTEN arm open

Coord: Daniel Na

Accrual: 1/3

[ETCTN 10186 \(opened on 1/31/24\)](#)

Phase II: Nivo + Ipi + Radiosurgery

[Meningioma grade II and III](#)

Coord: Tatsuya Tojima

[Accrual: 0/4](#)

[A071601](#)

Only recurrent arm open

Coord: Hanh Ngo

Accrual: 3/5



2L

NRG BN012
Phase III: Pre-operative Stereotactic RT vs
Post-operative Stereotactic RT
1-4 lesions; only 1 resectable
Coord: Daniel Na
Accrual: 2/6



Rare CNS Cancers / PCNS Lymphoma

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

PCNSL

1L

2L

UCI 21-77
Part A: MTR + Tirabrutinib

Coord: Daniel Na
Accrual: 1/6

Rare CNS cancers

UCI 20-152
Cohort 2 open (non-heavily pre-treated)

Histologically proven Ependymoma, Medulloblastoma, Parenchymal Pineal Region Tumors, Choroid Plexus, Histone Mutated Gliomas, Gliomatosis Cerebri, ATRT, Malignant/Atypical Meningioma*, Gliosarcoma or Primary CNS Sarcoma, Pleomorphic Xanthoastrocytoma, and Anaplastic Pleomorphic Xanthoastrocytoma, and tumors formerly known as Primitive Neuro-Ectodermal Tumors

Coord: Daniel Na
Accrual: 7/10